Scientific Article
previous document  unige:10954  next document
add to browser collection
Title

Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse

Authors
Owen, K. L.
Shibata, T.
Walker, S. E.
Published in Journal of Biological Response Modifiers. 1989, vol. 8, no. 4, p. 366-374
Abstract New Zealand Black/New Zealand White (NZB/W) mice, a model of systemic lupus erythematosus (SLE), have age-dependent loss of interleukin-2 (IL-2) production. To determine if replacement therapy would influence the course of autoimmune disease, we injected groups of NZB/W mice with low-dose (1,500 units/day) or high-dose (15,000 units/day) purified human recombinant IL-2. Parameters of active SLE and populations of splenocytes were not altered consistently by long-term treatment with either dose of IL-2.
Keywords AnimalsAutoantibodiesDisease Models, AnimalDose-Response Relationship, DrugFemaleFlow CytometryFluorescent Antibody TechniqueGlycoproteins/bloodHematologic TestsImmunoglobulins/analysisInterleukin-2/administration & dosage/ therapeutic useLupus Erythematosus, Systemic/ drug therapy/mortalityMaleMiceRecombinant Proteins/administration & dosage/therapeutic use
Identifiers
PMID: 2666586
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
Citation
(ISO format)
OWEN, K. L. et al. Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse. In: Journal of Biological Response Modifiers, 1989, vol. 8, n° 4, p. 366-374. https://archive-ouverte.unige.ch/unige:10954

185 hits

0 download

Update

Deposited on : 2010-08-26

Export document
Format :
Citation style :